Correction: “Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review”

Errata

This article corrects:

  1. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review Volume 53, Issue 6, 2121–2129, Article first published online: 25 May 2011

In the June 2011 issue of HEPATOLOGY, in the article entitled “Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review” (volume 53, pages 2121-2129) the data in Tables 2 and 3 are to be corrected as listed below:

Table 2. HBsAg and HBV DNA Cutoffs Proposed for Differentiating True Inactive Carriers From Patients With Reactivated HBsAg-Negative Disease
ParameterPerformancePatients (n)Reference
HBsAg < 1000 IU/mL and HBV DNA ≤ 2000 IU/mLDiagnostic accuracy fro identifying inactive carriers (genotype D) = 94.3% sensitivity = 91.1%, specificity = 95.4%, PPV = 87.9%, NPV = 96.7%20916
HBsAg < 3500 IU/mLNPV for reactivation = 95%3015
HBsAg ≤ 2000 IU/mL alonePPV for inactive carriers = 92.5%12217
+ HBV DNA ≤ 2000 IU/mLPPV = 100%  
HBsAg < 1000 IU/mL and HBV DNA < 2000 IU/mLFor inactive carriers Sensitivity = 74.3%, specificity = 87.5%, predictive value = 89.7%24219
Table 3. Decline of HBsAg Levels During Therapy
ReferenceIFN/PEG-IFNPEG-IFN and NANAComment
  • §

    For comparison only (this was not a randomized controlled trial).

  • *,†,‡: comparison of data with same marker.

HBeAg-positive    
25PEG-IFN: −0.8 log10 IU/mL (−0.9 log10 IU/mL)+LAM −1.1 log10 IU/mL (−1.3 log10 IU/mL)LAM: −0.4 log10 IU/mLFrom the baseline to week 48
26PEG-IFN: −0.87 log10 IU/mL*+LAM: −1.46 log10 IU/mL* From the baseline to week 48 (P = 0.04)*
27PEG-IFN: −0.4 log10 IU/mL+LOT: −1.3 log10 IU/mLLOT: −0.4 log10 IU/mLFrom the baseline to week 24
28  ETV: −0.4 log10 IU/mLFrom the baseline to month 12 (P < 0.001)
29PEG-IFN: −0.9 log10 IU/mL† ETV: −0.4 log10 IU/mL†From the baseline to week 48 (P > 0.05)†§
30  LOT: −0.5 log10 IU/mLFrom the baseline to week 48
   LOT: −0.8 log10 IU/mLFrom the baseline to year 3
31  TDF: 0.3 log10 IU/mLFrom the baseline to week 48
HBeAg-negative    
22IFN: 129 IU/mL/month LAM: 13.2 IU/mL/monthP = 0.032 for IFN versus LAM§
32PEG-IFN: −0.71 log10 IU/mL+LAM: −0.67 log10 IU/mLLAM: −0.02 log10 IU/mLFrom the baseline to week 48
33PEG-IFN: −0.75 log10 IU/mL+LAM: −0.6 log10 IU/mLLAM: −0.1 log10 IU/mLFrom the baseline to week 48
29PEG-IFN: −0.6 log10 IU/mL‡ ETV: +0.1 log10 IU/mL‡From the baseline to week 48. (P < 0.001)‡§
34 ±RBV: −0.47 log10 IU/mL From the baseline to week 48 (P < 0.001)

On page 2124, under the heading “Predicting responses to IFN-based therapy with HBsAg Levels”, the percentages in the first sentence are 35 and 25, respectively:

Because a sustained response to pegylated interferon (PEG-IFN) is achieved in only approximately 35% of HBeAg-positive patients and 25% of HBeAg-negative patients, identifying a potential treatment success is valuable for both the patient and the physician. A number of groups have retrospectively analyzed response rates in PEG-IFN cohorts with respect to on-treatment HBsAg declines.

The revised article in its entirety may be found in the online version of this issue.

Ancillary